Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews what is known about the functions of poly (ADP-ribose) polymerase (PARP) and outlines the rational development of PARP inhibitors as anticancer agents for tumours associated with BRCA gene mutations. Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.

This programme is supported by BioMarin Pharmaceutical

Year of Production:
Running Time:


Comments are closed.